Sponsor: 
GlaxoSmithKline Australia
Administration route: 
Intramuscular injection
Vaccine group: 
Meningococcal B vaccines

Registered for use in people aged ≥2 months.

MenB-MC — recombinant multicomponent meningococcal serogroup B vaccine

Each 0.5 mL monodose pre-filled syringe contains:

  • 50 µg Neisseria meningitidis serogroup B Neisseria heparin binding antigen fusion protein
  • 50 µg Neisseria meningitidis serogroup B Neisseria adhesion A protein
  • 50 µg Neisseria meningitidis serogroup B factor H binding protein fusion protein
  • 25 µg outer membrane vesicles from Neisseria meningitidis serogroup B strain NZ98/254 (measured as amount of total protein containing the PorA P1.4)

Adsorbed onto 0.5 mg aluminium hydroxide.

The product information and consumer medicine information for Bexsero have more details.

Audience: 
Infants and children
Previous

BCG Vaccine

Next

Boostrix

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018